We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.71B
AUM Growth
-$646M
Cap. Flow
+$138M
Cap. Flow %
3.73%
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$76.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
3
FOLD
Amicus Therapeutics
FOLD
+$33.6M
4
AMRN
Amarin Corp
AMRN
+$25M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$21.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
2
ARRY
Array Biopharma Inc
ARRY
+$48.1M
3
BPMC
Blueprint Medicines
BPMC
+$28.5M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24M
5
QURE icon
uniQure
QURE
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 93.8%
2 Financials 0.46%
3 Consumer Discretionary 0.18%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
26
Crinetics Pharmaceuticals
CRNX
$8.88B
$38.9M 1.05%
2,587,953
– –
TVTX icon
27
Travere Therapeutics
TVTX
$5.19B
$37.9M 1.02%
3,270,571
-502,011
-13% -$8.3M
MNTA
28
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$37.6M 1.01%
2,905,000
– –
ALBO
29
DELISTED
Albireo Pharma Inc
ALBO
$34.1M 0.92%
1,704,330
– –
FOMX
30
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$34.1M 0.92%
11,203,881
+6,542,057
+140% +$18.4M
ONCE
31
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$33.9M 0.91%
350,000
– –
KDMN
32
DELISTED
Kadmon Holdings, Inc.
KDMN
$33.2M 0.89%
13,165,746
– –
DBVT
33
DBV Technologies
DBVT
$807M
$31M 0.84%
360,908
– –
EIDX
34
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$24.7M 0.67%
686,992
– –
CTMX icon
35
CytomX Therapeutics
CTMX
$694M
$24M 0.65%
3,253,923
+100,000
+3% +$986K
ESTA icon
36
Establishment Labs
ESTA
$2.72B
$23.8M 0.64%
1,260,528
– –
NVTA
37
DELISTED
Invitae Corporation
NVTA
$23.1M 0.62%
1,198,182
-145,309
-11% -$3.43M
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$344M
$23M 0.62%
1,977,412
– –
TPTX
39
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$22.5M 0.6%
597,190
+172,222
+41% +$7.5M
YMAB
40
DELISTED
Y-mAbs Therapeutics
YMAB
$22.3M 0.6%
+854,940
New +$21.8M
RGNX icon
41
Regenxbio
RGNX
$620M
$21.6M 0.58%
608,000
-362,997
-37% -$14.7M
BIO icon
42
Bio-Rad Laboratories Class A
BIO
$8.76B
$21.6M 0.58%
+65,000
New +$21.2M
UROV
43
DELISTED
Urovant Sciences Ltd.
UROV
$21.3M 0.57%
2,246,547
+371,121
+20% +$3.22M
EHTH icon
44
eHealth
EHTH
$42.5M
$17M 0.46%
255,089
-130,893
-34% -$11.8M
VAPO
45
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$16.7M 0.45%
220,559
+45,000
+26% +$5.23M
ALDX icon
46
Aldeyra Therapeutics
ALDX
$95.9M
$16.3M 0.44%
3,085,458
– –
MMSI icon
47
Merit Medical Systems
MMSI
$4.81B
$16.1M 0.43%
528,788
-288,421
-35% -$11.7M
STOK icon
48
Stoke Therapeutics
STOK
$1.85B
$14.4M 0.39%
671,978
– –
MTEM
49
DELISTED
Molecular Templates, Inc.
MTEM
$13M 0.35%
131,609
– –
CNCE
50
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$12.9M 0.35%
2,194,641
-10,000
-0.5% -$106K
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Perceptive Advisors deployed $138M of net new capital in Q3 2019, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $28.5M trimmed.

  • Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
  • Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
  • Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
  • Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
  • Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.